{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:22:12Z","timestamp":1778224932759,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1023\/a:1020840311573","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T20:57:25Z","timestamp":1048021045000},"page":"159-166","source":"Crossref","is-referenced-by-count":37,"title":["Osteoporosis and Other Adverse Body Composition Changes during Androgen Deprivation Therapy for Prostate Cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Matthew R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5095692_CR1","first-page":"20","volume":"54","author":"NA Siddiqui","year":"1999","unstructured":"Siddiqui NA, Shetty KR, Duthie EH Jr: Osteoporosis in older men: Discovering when and how to treat it. Geriatrics 54: 20\u201322, 27\u201328, 30, 1999","journal-title":"Geriatrics"},{"key":"5095692_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S8756-3282(99)00117-9","volume":"25","author":"E Seeman","year":"1999","unstructured":"Seeman E: The structural basis of bone fragility in men. Bone 25: 143\u2013147, 1999","journal-title":"Bone"},{"key":"5095692_CR3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1990.03440050059033","volume":"263","author":"SR Cummings","year":"1990","unstructured":"Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P: Appendicular bone density and age predict hip fracture in women. The study of osteoporotic fractures research group. JAMA 263: 665\u2013668, 1990","journal-title":"JAMA"},{"key":"5095692_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","volume":"341","author":"SR Cummings","year":"1993","unstructured":"Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM: Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lan 341: 72\u201375, 1993","journal-title":"Lan"},{"key":"5095692_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/8756-3282(90)90074-9","volume":"11","author":"P Gardsell","year":"1990","unstructured":"Gardsell P, Johnell O, Nilsson BE: The predictive value of forearm bone mineral content measurements in men. Bone 11: 229\u2013232, 1990","journal-title":"Bone"},{"key":"5095692_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-115-11-837","volume":"115","author":"DG Seeley","year":"1991","unstructured":"Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR: Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group. Ann Intern Med 115: 837\u2013842, 1991","journal-title":"Ann Intern Med"},{"key":"5095692_CR7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","volume":"338","author":"R Eastell","year":"1998","unstructured":"Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736\u2013746, 1998","journal-title":"N Engl J Med"},{"key":"5095692_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9: 1137\u20131141, 1994","journal-title":"J Bone Miner Res"},{"key":"5095692_CR9","first-page":"3431","volume":"84","author":"JP Bilezikian","year":"1999","unstructured":"Bilezikian JP: Osteoporosis in men. J Clin Endocrinol Metab 84: 3431\u20133434, 1999","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91: 2238\u20132245, 2001","journal-title":"Cancer"},{"key":"5095692_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S8756-3282(99)00255-0","volume":"26","author":"P Szulc","year":"2000","unstructured":"Szulc P, Marchand F, Duboeuf F, Delmas PD: Cross-sectional assessment of age-related bone loss in men: The MINOS study. Bone 26: 123\u2013129, 2000","journal-title":"Bone"},{"key":"5095692_CR12","first-page":"2670","volume":"85","author":"PJ Snyder","year":"2000","unstructured":"Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL: Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670\u20132677, 2000","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","volume":"21","author":"N Zojer","year":"1999","unstructured":"Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21: 389\u2013406, 1999","journal-title":"Drug Saf"},{"key":"5095692_CR14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1359\/jbmr.2000.15.7.1417","volume":"15","author":"JM Zmuda","year":"2000","unstructured":"Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS: Posterior\u2013anterior and lateral dual-energy X-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 15: 1417\u20131424, 2000","journal-title":"J Bone Miner Res"},{"key":"5095692_CR15","first-page":"724","volume":"78","author":"JS Finkelstein","year":"1994","unstructured":"Finkelstein JS, Cleary RL, Butler JP, Antonelli R, Mitlak BH, Deraska DJ, Zamora-Quezada JC, Neer RM: A comparison of lateral versus anterior\u2013posterior spine dual energy X-ray absorptiometry for the diagnosis of osteopenia. J Clin Endocrinol Metab 78: 724\u2013730, 1994","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0033-8389(22)00360-8","volume":"31","author":"S Grampp","year":"1993","unstructured":"Grampp S, Jergas M, Gluer CC, Lang P, Brastow P, Genant HK: Radiologic diagnosis of osteoporosis. Current methods and perspectives. Radiol Clin North Am 31: 1133\u20131145, 1993","journal-title":"Radiol Clin North Am"},{"key":"5095692_CR17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1210\/jcem-70-3-705","volume":"70","author":"R Pacifici","year":"1990","unstructured":"Pacifici R, Rupich R, Griffin M, Chines A, Susman N, Avioli LV: Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J Clin Endocrinol Metab 70: 705\u2013710, 1990","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos Int 11: S2\u2013S17, 2000","journal-title":"Osteoporos Int"},{"key":"5095692_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00355381","volume":"10","author":"HE Schutte","year":"1983","unstructured":"Schutte HE, Park WM: The diagnostic value of bone scintigraphy in patients with low back pain. Skeletal Radiol 10: 1\u20134, 1983","journal-title":"Skeletal Radiol"},{"key":"5095692_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0889-8529(05)70009-8","volume":"27","author":"ES Orwoll","year":"1998","unstructured":"Orwoll ES: Osteoporosis in men. Endocrinol Metab Clin North Am 27: 349\u2013367, 1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"5095692_CR21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","volume":"157","author":"HW Daniell","year":"1997","unstructured":"Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 157: 439\u2013444, 1997","journal-title":"J Urol"},{"key":"5095692_CR22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","volume":"79","author":"MF Townsend","year":"1997","unstructured":"Townsend MF, Sanders WH, Northway RO, Graham SD Jr: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79: 545\u2013550, 1997","journal-title":"Cancer"},{"key":"5095692_CR23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","volume":"86","author":"T Hatano","year":"2000","unstructured":"Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86: 449\u2013552, 2000","journal-title":"BJU Int"},{"key":"5095692_CR24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","volume":"166","author":"MG Oefelein","year":"2001","unstructured":"Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M: Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. J Urol 166: 1724\u20131728, 2001","journal-title":"J Urol"},{"key":"5095692_CR25","first-page":"155","volume":"9","author":"BT Burton","year":"1985","unstructured":"Burton BT, Foster WR, Hirsch J, Van Itallie TB: Health implications of obesity: An NIH Consensus Development Conference. Int J Obes 9: 155\u2013170, 1985","journal-title":"Int J Obes"},{"key":"5095692_CR26","first-page":"288","volume":"76","author":"D Goldray","year":"1993","unstructured":"Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 76: 288\u2013290, 1993","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","volume":"57","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Eriksson A, Stege R, Carlstrom K: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57: 97\u201399, 1995","journal-title":"Calcif Tissue Int"},{"key":"5095692_CR28","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","volume":"83","author":"T Diamond","year":"1998","unstructured":"Diamond T, Campbell J, Bryant C, Lynch W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83: 1561\u20131566, 1998","journal-title":"Cancer"},{"key":"5095692_CR29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"JF Maillefert","year":"1999","unstructured":"Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161: 1219\u20131222, 1999","journal-title":"J Urol"},{"key":"5095692_CR30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181\u2013186, 2000","journal-title":"J Urol"},{"key":"5095692_CR31","first-page":"442","volume":"58","author":"E Giovannucci","year":"1998","unstructured":"Giovannucci E, Rimm EB, Wolk A, et al.: Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58: 442\u2013447, 1998","journal-title":"Cancer Res"},{"key":"5095692_CR32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1023\/A:1008823601897","volume":"9","author":"JM Chan","year":"1998","unstructured":"Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A: Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9: 559\u2013566, 1998","journal-title":"Cancer Causes Control"},{"key":"5095692_CR33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1023\/A:1008835903714","volume":"9","author":"E Giovannucci","year":"1998","unstructured":"Giovannucci E: Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis. Cancer Causes Control 9: 567\u2013582, 1998","journal-title":"Cancer Causes Control"},{"key":"5095692_CR34","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345: 948\u2013955, 2001","journal-title":"N Engl J Med"},{"key":"5095692_CR35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K: Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604\u2013610, 2000","journal-title":"N Engl J Med"},{"key":"5095692_CR36","unstructured":"Novartis-Oncology. Data on file. 2001"},{"key":"5095692_CR37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1172\/JCI119701","volume":"100","author":"CW Slemenda","year":"1997","unstructured":"Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC: Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100: 1755\u20131759, 1997","journal-title":"J Clin Invest"},{"key":"5095692_CR38","first-page":"2266","volume":"83","author":"S Khosla","year":"1998","unstructured":"Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83: 2266\u20132274, 1998","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR39","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1359\/jbmr.1997.12.11.1833","volume":"12","author":"GA Greendale","year":"1997","unstructured":"Greendale GA, Edelstein S, Barrett-Connor E: Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 12: 1833\u20131843, 1997","journal-title":"J Bone Miner Res"},{"key":"5095692_CR40","first-page":"219","volume":"85","author":"E Barrett-Connor","year":"2000","unstructured":"Barrett-Connor E, Mueller JE, von Muhlen DG, Laughlin GA, Schneider DL, Sartoris DJ: Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 85: 219\u2013223, 2000","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","volume":"331","author":"EP Smith","year":"1994","unstructured":"Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056\u20131061, 1994","journal-title":"N Engl J Med"},{"key":"5095692_CR42","first-page":"3689","volume":"80","author":"A Morishima","year":"1995","unstructured":"Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689\u20133698, 1995","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199808273390905","volume":"339","author":"JP Bilezikian","year":"1998","unstructured":"Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339: 599\u2013603, 1998","journal-title":"N Engl J Med"},{"key":"5095692_CR44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0889-8588(05)70364-6","volume":"10","author":"M Robson","year":"1996","unstructured":"Robson M, Dawson N: How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 10: 727\u2013747, 1996","journal-title":"Hematol Oncol Clin North Am"},{"key":"5095692_CR45","first-page":"267","volume":"4","author":"JW Moul","year":"2000","unstructured":"Moul JW: Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol 4: 267\u2013272, 2000","journal-title":"Mol Urol"},{"key":"5095692_CR46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0090-4295(98)00004-1","volume":"51","author":"P Iversen","year":"1998","unstructured":"Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51: 389\u2013396, 1998","journal-title":"Urology"},{"key":"5095692_CR47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000019634","volume":"33","author":"CJ Tyrrell","year":"1998","unstructured":"Tyrrell CJ, Kaisary AV, Iversen P, et al.: A randomised comparison of \u2018Casodex\u2019 (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447\u2013456, 1998","journal-title":"Eur Urol"},{"key":"5095692_CR48","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1999.17.7.2027","volume":"17","author":"F Boccardo","year":"1999","unstructured":"Boccardo F, Rubagotti A, Barichello M, et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian prostate cancer project study. J Clin Oncol 17: 2027\u20132038, 1999","journal-title":"J Clin Oncol"},{"key":"5095692_CR49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","volume":"41","author":"J Verhelst","year":"1994","unstructured":"Verhelst J, Denis L, Van Vliet P, et al.: Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 41: 525\u2013530, 1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5095692_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000052546","volume":"39","author":"PA Abrahamsson","year":"2001","unstructured":"Abrahamsson PA: Treatment of locally advanced prostate cancer \u2013 a new role for antiandrogen monotherapy? Eur Urol 39: 22\u201328, 2001","journal-title":"Eur Urol"},{"key":"5095692_CR51","first-page":"110","volume":"22","author":"A Vermeulen","year":"1999","unstructured":"Vermeulen A, Goemaere S, Kaufman JM: Testosterone, body composition and aging. J Endocrinol Invest 22: 110\u2013116, 1999","journal-title":"J Endocrinol Invest"},{"key":"5095692_CR52","first-page":"2647","volume":"84","author":"PJ Snyder","year":"1999","unstructured":"Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84: 2647\u20132653, 1999","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","volume":"283","author":"S Bhasin","year":"2000","unstructured":"Bhasin S, Storer TW, Javanbakht M, et al.: Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283: 763\u2013770, 2000","journal-title":"JAMA"},{"key":"5095692_CR54","first-page":"60","volume":"85","author":"S Grinspoon","year":"2000","unstructured":"Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A: Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 85: 60\u201365, 2000","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR55","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.1996.00440100065008","volume":"156","author":"IR Reid","year":"1996","unstructured":"Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 156: 1173\u20131177, 1996","journal-title":"Arch Intern Med"},{"key":"5095692_CR56","first-page":"4358","volume":"81","author":"L Katznelson","year":"1996","unstructured":"Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A: Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358\u20134365, 1996","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR57","first-page":"407","volume":"82","author":"S Bhasin","year":"1997","unstructured":"Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82: 407\u2013413, 1997","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR58","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/0026-0495(90)90190-N","volume":"39","author":"JA Tayek","year":"1990","unstructured":"Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 39: 1314\u20131319, 1990","journal-title":"Metabolism"},{"key":"5095692_CR59","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","volume":"86","author":"JC Smith","year":"2001","unstructured":"Smith JC, Bennett S, Evans LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261\u20134267, 2001","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87: 599\u2013603, 2002","journal-title":"J Clin Endocrinol Metab"},{"key":"5095692_CR61","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0959-8049(00)00084-8","volume":"36","author":"P Stone","year":"2000","unstructured":"Stone P, Hardy J, Huddart R, A'Hern R, Richards M: Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36: 1134\u20131141, 2000","journal-title":"Eur J Cancer"},{"key":"5095692_CR62","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0022-5347(05)67533-7","volume":"163","author":"HW Herr","year":"2000","unstructured":"Herr HW, O'sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163: 1743\u20131746, 2000","journal-title":"J Urol"},{"key":"5095692_CR63","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","volume":"19","author":"AL Potosky","year":"2001","unstructured":"Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM: Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 19: 3750\u20133757, 2001","journal-title":"J Clin Oncol"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020840311573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1020840311573\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020840311573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:17:48Z","timestamp":1750961868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1020840311573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["5095692"],"URL":"https:\/\/doi.org\/10.1023\/a:1020840311573","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}